The Clinical Pharmacology of Misonidazole in Radiation Therapy Oncology Group Trials

  • Theodore L. Phillips
  • Todd H. Wasserman
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 42)


Because the effectiveness of a hypoxic cell sensitizer of the imidazole class depends directly on its concentration in serum and within the tumor, the pharmacologic distribution of these drugs is of extreme importance. Numerous reports including those originally of Adams and colleagues (1), McNally (2) and of Denekamp (3) have indicated as well as have the skin experiments of Dische and colleagues (4), that the enhancement ratio observable is closely tied to the concentration in tumor and serum. The concentrations versus effectiveness curve for misonidazole rises steeply so that enhancement ratios between 1.3 and 1.5 may be observed at concentrations as low as 25–30 μg/ml within tumor. For these reasons, the determination of concentration within tumor and serum, a more readily-measurable quantity, has been extremely important in the Phase I and II studies of the RTOG (5–9).


High Performance Liquid Chromatography Roswell Park Memorial Institute Hypoxic Cell Enhancement Ratio High Performance Liquid Chromatography Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. E. Adams, I. R. Flockhart, C. E. Smithen, I. J. Stratford, P. Wardman and M. E. Watts, Electron-affinie sensitization. A correlation between structures, one-electron reduction potential, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers, Radiat. Res., 67: 9 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    N. J. McNally, J. Denekamp, P. Sheldon, I. R. Flockhart and F. A. Stewart, Radiosensitization by misonidazole (Ro 07- 0582). The importance of timing and tumour concentration of sensitizer, Radiat. Res., 73: 568 (1978).PubMedCrossRefGoogle Scholar
  3. 3.
    J. Denekamp, Testing of hypoxic cell radiosensitizers in vivo, Cancer Clin. Trials, 3: 139 (1980).PubMedGoogle Scholar
  4. 4.
    S. Dische, A. J. Gray and G. D. Zanelli, Clinical testing of the radiosensitizer Ro 07-0582, II Radiosensitization of normal and hypoxic skin, Clin. Radiol. 27: 159 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    T. L. Phillips, T. H. Wasserman, R. J. Johnson, The hypoxic cell sensitizer program in the U.S., Br. J. Cancer, 37: 276, Suppl. I II (1978).Google Scholar
  6. 6.
    T. L. Phillips and T. H. Wasserman, Hypoxic cell sensitizer studies in the U.S., in “The Treatment of Radioresistant Cancers”, Elsevier/North Holland Press, 29 (1979).Google Scholar
  7. 7.
    T. L. Phillips, T. H. Wasserman, R.J. Johnson, Final Report on the United States Phase I clinical trial of the hypoxic cell radiosensitizer, misonidazole. Submitted to Cancer (1980).Google Scholar
  8. 8.
    T. H. Wasserman, T. L. Phillips, R. J. Johnson, Initial U.S. clinical and pharmacologic evaluation of misonidazole, an hypoxic cell radiosénsitizer, Int. J. Radiat. One. Biol. Phys., 5: 775 (1979).CrossRefGoogle Scholar
  9. 9.
    T. H. Wasserman, J. Stetz and T. L. Phillips, Clinical Trials of misonidazole in the U.S. In press, Cancer Clin. Trials (1980).Google Scholar
  10. 10.
    R. A. Marqués, B. Stafford, N. Flynn and W. Sadee, Determinations of metronidazole and misonidazole and their metabolites in plasma and urine by high performance liquid chromatography, J. Chromatog., 146: 163 (1978).CrossRefGoogle Scholar
  11. 11.
    G. Van Raalte, T. L. Phillips and T. H. Wasserman, Bioavailability of misonidazole in capsule and tablet form, (abstract) in press,Int. J. Radiat. One. Biol. Phys. (1980).Google Scholar
  12. 12.
    T. H. Wasserman, R. Urtasun and J. Schwade, The neurotoxicity of misonidazole: Potential modifying role of phenytoin sodium and dexamethasone, Br. J. Radiol., 53: 173 (1980).CrossRefGoogle Scholar
  13. 13.
    P. Workman, Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of miso-nidazole in mice, Br. J. Cancer, 40: 335 (1979).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Theodore L. Phillips
    • 1
    • 2
  • Todd H. Wasserman
    • 1
    • 2
  1. 1.Department of Radiation OncologyUniversity of CaliforniaSan FranciscoUSA
  2. 2.Department of Radiation OncologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations